I
Intergalactic Therapeutics
An ATP company revolutionizing gene therapies with a novel non-viral platform
About Intergalactic Therapeutics
Intergalactic Therapeutics, founded by ATP Apple Tree Partners, is pioneering the next generation of life sciences companies with a focus on non-viral gene therapy. Traditional gene therapies often use viruses to deliver genetic material into cells, but this method can have significant limitations and risks. Intergalactic Therapeutics aims to overcome these challenges by developing a best-in-class, non-viral alternative. This innovative approach has the potential to transform the field of gene therapy, making treatments safer and more effective.
The company serves a diverse range of clients, including pharmaceutical companies, research institutions, and healthcare providers. These clients are looking for advanced solutions to treat genetic disorders and other serious medical conditions. By offering a non-viral gene therapy platform, Intergalactic Therapeutics addresses a critical need in the market for safer and more efficient genetic treatments.
Intergalactic Therapeutics operates in the highly competitive and rapidly evolving biotechnology market. This market is characterized by significant research and development (R&D) investments, stringent regulatory requirements, and a constant demand for innovative therapies. The company's business model is centered around developing and commercializing its proprietary non-viral gene therapy technology. It generates revenue through partnerships, licensing agreements, and potentially direct sales of its therapeutic products once they receive regulatory approval.
The company is led by a team of experienced professionals, including Anna Batarina, CFA, a partner at ATP with a strong background in international business and capital markets, and Charles Allen, CPA, Vice President of Finance Operations, who brings extensive experience from leading biotech firms. Their combined expertise in finance, strategy, and biotechnology positions Intergalactic Therapeutics for success in its mission to revolutionize gene therapy.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Oct 2021 | $75M | $300M | Apple Tree Partners | — |
| SEEDOther financing | Jan 2021 | $0 | — | Apple Tree Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Intergalactic Therapeutics is 270 monthly website visits, down 58.5% over the last three months. Intergalactic Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Apple Tree Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Intergalactic Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Intergalactic Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.